Stockreport

Goldman Sachs Upgrades Beta Bionics (BBNX) to Buy, Raises PT to $26 on Strong Growth and Market Outlook [Yahoo! Finance]

Beta Bionics, Inc.  (BBNX) 
PDF Buy from Neutral with a price target of $26, which was upgraded from $18. Goldman Sachs' analysis of the diabetes technology market shows sustained growth and profitabil [Read more]